The U.S. Food and Drug Administration has approved Johnson & Johnson's (NYSE: JNJ) IMAAVY (nipocalimab-aahu) for the treatment of warm ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE